Abstract:Introduction: Breast cancer is the most common type of cancer seen in women in western countries. Thus, diagnostic modalities sensitive to early-stage breast cancer are needed. Antibody-based array platforms of a data-driven type, which are expected to facilitate more rapid and sensitive detection of novel biomarkers, have emerged as a direct, rapid means for profiling cancer-specific signatures using small samples. In line with this concept, our group constructed an antibody bead array panel for 35 analytes that were selected during the discovery step. This study was aimed at testing the performance of this 35-plex array panel in profiling signatures specific for primary non-metastatic breast cancer and validating its diagnostic utility in this independent population. Methods: Thirty-five analytes were selected from more than 50 markers through screening steps using a serum bank consisting of 4,500 samples from various types of cancer. An antibody-bead array of 35 markers was constructed using the Luminex bead array platform. A study population consisting of 98 breast cancer patients and 96 normal subjects was analysed using this panel. Multivariate classification algorithms were used to find discriminating biomarkers and validated with another independent population of 90 breast cancer and 79 healthy controls. Results: Serum concentrations of epidermal growth factor, soluble CD40-ligand and proapolipoprotein A1 were increased in breast cancer patients. High-molecular-weight-kininogen, apolipoprotein A1, soluble vascular cell adhesion molecule-1, plasminogen activator inhibitor-1, vitamin-D binding protein and vitronectin were decreased in the cancer group. Multivariate classification algorithms distinguished breast cancer patients from the normal population with high accuracy (91.8% with random forest, 91.5% with support vector machine, 87.6% with linear discriminant analysis). Combinatorial markers also detected breast cancer at an early stage with greater sensitivity. Conclusions: The current study demonstrated the usefulness of the antibody-bead array approach in finding signatures specific for primary non-metastatic breast cancer and illustrated the potential for early, high sensitivity detection of breast cancer. Further validation is required before array-based technology is used routinely for early detection of breast cancer.

Serial Analysis of 38 Proteins during the Progression of Human Breast Tumor in Mice Using an Antibody Colocalization Microarray*[S]

[Proteome analysis for identification of tumor-associated biomarkers in breast cancer].

Human Mammaglobin: a Superior Marker for Reverse-Transcriptase PCR in Detecting Circulating Tumor Cells in Breast Cancer Patients

Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human

A serum glycomics approach to breast cancer biomarkers

Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology.

Isobaric Tags for Relative and Absolute Quantitation in Proteomic Analysis of Potential Biomarkers in Invasive Cancer, Ductal Carcinoma <i>In Situ</i>, and Mammary Fibroadenoma

Isobaric Tags for Relative and Absolute Quantitation in Proteomic Analysis of Potential Biomarkers in Invasive Cancer, Ductal Carcinoma In Situ, and Mammary Fibroadenoma

Use of Serological Proteomic Methods to Find Biomarkers Associated with Breast Cancer

Breast cancer plasma protein biomarker discovery by coupling LC-MS/MS proteomics and systems biology

Antibody microarray profiling of human prostate cancer sera: Antibody screening and identification of potential biomarkers

A Proteomics Platform Combining Depletion, Multi-Lectin Affinity Chromatography (M-Lac), and Isoelectric Focusing to Study the Breast Cancer Proteome

Microarrays of Tumor Cell Derived Proteins Uncover a Distinct Pattern of Prostate Cancer Serum Immunoreactivity.

Serum protein profiling reveals an inflammation signature as a predictor of early breast cancer survival

Comparative Proteome Analysis of Breast Cancer and Normal Breast

Identification of Breast Cancer Metastasis‐associated Proteins in an Isogenic Tumor Metastasis Model Using Two‐dimensional Gel Electrophoresis and Liquid Chromatography‐ion Trap‐mass Spectrometry

Detection and Identification of Serum Protein Peak at 6648 M/z As a Novel Indicator in Breast Cancer Based on Mass Spectrometry.

The multiplex bead array approach to identifying serum biomarkers associated with breast cancer

Enhanced Protein Profiling Arrays with Elisa-Based Amplification for High-Throughput Molecular Changes of Tumor Patients' Plasma

Mass Spectrometry (LC–MS/MS) Identified Proteomic Biosignatures of Breast Cancer in Proximal Fluid

Analysis of multiple proteins in a cancer mouse model using snap chip